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 The suicide gene therapy for hepatocellular carcinoma 
(HCC) has given some promise, but the toxicity of adenovirus-
mediated gene delivery using the cytomegalovirus promoter 
(CMV) region linked to herpes simplex virus thymidine kinase 
gene (HSV-TK) in combination with ganciclovir (GCV) ther-
apy was reported. In this study, to improve the technical issue 
of conventional gene therapy, we examined the usefulness 
of hemagglutinating virus of Japan (HVJ)-anionic-liposome-
mediated CMV-TK/GCV as an introductory target gene and 
development the selective application of alpha-fetoprotein 
(AFP) enhancer/promoter or heat shock protein (HSP) pro-
moter for gene therapy. 
 By the luciferase reporter gene assay, both HVJ-liposome 
transfection and the transcriptional activation of AFP 
enhancer/promoter or that of the HSP promoter by heat treat-
ment were found to be quite effective in vivo and in vivo/in 
vitro models respectively. The toxicity of HVJ-anionic 
liposome-mediated gene therapy was smaller than that of 
adenovirus-driven approach as judged by histopathological 
examination of experimental animals' liver and GPT blood 
test. Thus, the HVJ-liposome-mediated AFP-TK/GCV or HSP-
TK/GCV technique may be a potent and useful strategy of 
the gene therapy of HCC.
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Introduction 
 Hepatocelluar carcinoma (HCC) is one of major ma-
lignancies with poor prognosis and accounts for approxi-
mately 1,250,000 annual cancer deaths in the world"). 
For patients with advanced HCC, gene therapy may 
provide a potential treatment modality to prolong sur-
vival and improve quality of life, because of the lim-
ited efficiency of therapy and present therapeutics'-). 
 In cancer gene therapy, HSV-tk converts the nontoxic 
GCV to a highly toxic phosphorylated-GCV that acts 
as a chain terminator of DNA synthesis and an inhibi-
tor of DNA polymerase6-8>. Advantages of the HSV-tk 
system include lower toxicity for normal non-dividing 
cells and a bystander effect, in which HSV-tk-negative 
tumor cell death may be caused by neighboring HSV-
tk-positive tumor cells exposed to GCV9'. Retrovirus-
and adenovirus-mediated HSV-tk/ GCV treatment has 
been studied in HCC10-13' and the adenovirus approach 
was found to exhibit greater gene transfer efficiency 
than retrovirus-mediated one. However, it may provoke 
acute hepatitis and severe hepatotoxic side effects dur-
ing the course"-"). 
 Therefore, molecular targeting and safety vectors are 
utmost importance for the purpose of side effects re-
duction in suicide gene therapy"). Tissue- or tumor-
specific promoters offer an attractive approach from 
this point of view as such promoters are able to ex-
press a target gene in cell-type specific manner"-21'. 
Gene transduction efficiency using HVJ-liposome system 
in various tissues has been reported, and its associated 
low immunogenicity facilitates further investigation22,23' 
 In this view, we estimated the toxicity of CMV-TK 
/GCV therapy using HVJ-anionic-liposome method in 
vivo based on our experimental results, and further 
discuss the applicability of AFP-enhancer/promoter or 
HSP promoter for gene therapy of HCC.
Materials, methods and results 
Cell lines and animals 
 Three hepatoma cell lines with different AFP-produc-
ing characteristics, HuH7 is high AFP producer, HepG2-
moderate, PLC/PRF/5-low and Lovo cells (colon carci-
noma cell line, does not produce AFP) were used in the 
study. Experimental animals were male BALB/C-nu/nu 
mice. 
Preparation of HVJ-liposome 
 Hemagglutinating virus of Japan (HVJ)-liposome for 
in vivo experiment was prepared as described before"'. 
Phosphatidylserine (Avanti Polar Lipids, Inc., Alabama), 
phosphatidylcholine (Sigma Chemical Co., St. Louis, MO) 
and cholesterol (Sigma) were mixed in a weight ratio 
of 1:4.8:2. The lipid mixture (10 mg) was transferred into 
a. glass tube and dried to form a fine layer in a rotary 
evaporator (Iwaki Glass, Tokyo, Japan), and then hy-
drated in 200,ul of balanced salt solution (BSS; 137 mM 
NaC1, 5.4 mM KCI, 13 mM Tris-HCI, pH 7.6) containing 
DNA-high mobility group I complex, preincubated at 20 
°C for 1 h. The mixture was vortexed for 30 sec and then 
left to stand for 30 sec, the procedure was repeated eight 
times, and liposomes were finally formed by sonication, 
then incubated at 37C for 30 min with shaking at 120 per 
minute. In the next step, 10,000 hemagglutinating units 
(HAU) of purified HVJ inactivated by ultraviolet irradia-
tion (1980 J/m2) were slowly added to the liposome sus-
pension at 4°C during 10 min, then incubated at 37°C for 
60 min with shaking. Free HVJ was removed from the 
HVJ-liposome solution by gradient sucrose density cen-
trifugation. The second layer of sucrose containing the 
HVJ-liposome was collected. 
Promoter assay in vitro 
 To estimate the efficiency of human AFP-enhancer 
/promoter, its transcriptional activity was examined in 
vitro by means of dual luciferase reporter assay in three 
hepatoma cell lines and Lovo cells using the renilla luci-
ferase/cytomegalovirus promoter system as a reference. 
The AFP-enhancer/promoter activity in all cell lines 
was increased compared to that in Lovo cells: 858-fold 
in HuH7, 486-fold in HepG2, and 76-fold in PLC/PRF/5 
(Fig. 1(A)) (Miki et al., unpublished data). 
 The transcriptional activation of humane HSP pro-
moter was measured 6 h after heat treatment cells (43 
°C f
or 30min) and found to be elevated to 156-, 662-, 
and 59- times compared to in PLC/PRF/5, HepG2 and 
HuH7 cells, respectively (Fig. 1(B)) . 
In vitro gene therapy 
 AFP-tk gene was transferred into three different AFP 
producing hepatoma cell lines and Lovo cells using the 
HVJ-cationic-liposome241. Each cell line was subjected to 
the GCV-sensitivity test using 10 i M using mock gene-
transfected cells as a control. The survival of Lovo, 
PLC/PRF/5, HepG2 and HuH7 cells was 100%, 72%, 
44%, and 35%, respectively (Fig. 2A) (Miki et al., un-
published data). The killing effect of AFP-tk gene 
therapy was increased in prorate manner in cell lines 
according to their ability to produce AFP. Experiments 
with transferred HSP-tk gene were performed similarly 
to describe above. Cell survival of PLC/PRF/5, HepG2
Fig. 1. (A) AFP-enhancer/promoter activity in three-hepatoma cell lines and Lovo cells. Data represent fold acti-
vation of transcription activity compared to AFP-enhancer/promoter activity in Lovo. (Mean±SEM, n=4). 
(B) HSP-promoter activation in three-hepatoma cell lines by heat shock at 43°C for 30min. After heat shock, cells 
were incubated for 6h at 37 °C and harvested for luciferase assay. Fold activation is expressed as a relative 
luciferase activity for each cell line without heat treatment. (Mean±SEM, n=3).
and HuH7 were 59%, 35%, and 64%, respectively (Fig. 
2B). 
Promoter assay in vivo 
 To estimate the transfectional efficiency of HVJ-
anionic-liposome, the renilla luciferase gene driven by 
the cytomegalovirus promoter was used. Fig. 3A dem-
onstrated that the reporter gene was transfected not only 
into the tumor tissue but also into organs. However, 
after the heat treatment (43°C for 30min), significant 
induction of HSP-promoter activity in vivo was ob-
served mostly in the tumor, and less efficiency in other 
organs (Fig. 3B). And significant induction of AFP-
enhancer/promoter activity in vivo was observed mostly 
in the tumor, and less efficiency in other organs (data 
not shown).
In vivo experiment 
 The nude mice implanted with HCC were prepared 
as previously described"). These animals implanted 
with HCC (n=2) and without HCC (n=3) were injected 
intraperitoneally with HVJ-anionic-liposome containing 
CMV-tk (40ug) on day 0. GCV administration (20 mg/kg 
injected intraperitoneally) was initiated daily for 10 
days. 
 Number of white blood cell (WBC) count, serum level 
of blood urea nitrogen (BUN) and serum glutamic-
pyruvic transaminase (GPT) activity were measured at 
day 0, day 4, day 7 and day 10. To evaluate the toxicity of 
gene therapy, animals were sacrificed at 10 days after the 
end of GCV treatment and examined histopathologically. 
 One of two male nude mice implanted with HuH7 cells 
developed bloody ascites. WBC count was 1,000/ul, BUN
Fig. 2. Cell survival studies: (A) Lovo, PLC/PRF/5, HepG2, and HuH7 treated with GCV=10uM. In vitro gene 
therapy was carried out as follows. Group I; mock gene transfection as a control, Group II; AFP-tk transfection. 
Mock gene or AFP-tk plasmids were introduced into the cells using the HVJ-cationic liposome. 
(B): PLC/PRF/5, HepG2, and HuH7 treated with GCV=10pM. Group I, mock gene-transfected cells as a control; 
Group II, HSP-tk-transfected cells by heat treatment (43V 30min). With 10 u M GCV, percent survival in each 
group was standardized to cell number of Group I as a control (100%). (Mean±SEM, n=3)
Fig. 3. (A): The transfection efficiency by HVJ-anionic-liposome. Fold activation was standardized to the 
luciferase activity in tumor (100%). Reporter gene expression in liver, gut, kidney, and spleen was 133%, 99%, 
98%, and 136%, respectively. 
(B): HSP-promoter activation in vivo treated with heat shock at 43°C 30min. Six hour after heat shock, luciferase 
assay was performed (n=3). Fold induction was standardized to the luciferase activity in tumor (100%). Each 
data point represents mean±SEM
was 32 (mg/dl) and serum GPT activity was 79 (I.U./ 1) . 
The animal died 4 days after the beginning of GCV 
treatment. Pathological examination showed that liver 
had HCC tumor invasion and several areas of inflam-
mation (Figure 5A). 
 Blood test data from another mouse implanted with 
HCC cells are shown in Fig. 4A. WBC count and serum 
level of BUN were slightly increased after the gene 
therapy, while serum GPT activity increased up to 200 
(I.U./1) 7 days after GCV treatment. Blood test data 
from control mice are shown in Fig. 4B. Changes of 
WBC count and serum levels of BUN were not remark-
able, and serum GPT activities were not elevated after 
the gene therapy. 
 Histological pictures of liver tissue of a HCC im-
planted nude mouse, a nine-month-old nude mouse, and 
a five-week-old nude mouse is shown in Figure 5B, 5C, 
and 5D, respectively. In all areas examined, inflamma-
tion was moderate as shown in Figure 5B or minimal 
Figure 5C, 5D. The observations were consistent with 
the toxic effect of GCV rather than with the conse-
quence of transfection. 
 AFP-tk gene therapy was effective as same as the 
CMV promoter-mediated HSV-tk approach. Both of meth-
ods surpressed tumor growth of same extent (Table 1) 
(Miki et al., unpublished data). This facility suggests 
the limitation of the enhancement of promoter activity 
in suicide gene therapy of HCC.
Discussion 
 In the present study, we estimated the AFP-tk or HSP-
tk suicide gene therapy for HCC, examples of molecu-
lar targeting, under the control of human AFP gene 
enhancer/promoter or human HSP gene promoter. In the 
initial part of the study, we confirmed the transcriptional 
activity of AFP-enhancer/promoter and HSP-promoter. 
Transcriptional activity of human AFP-enhancer/ pro-
moter in hepatoma cell lines was increased to 76- to 
858-fold more than that in Lovo non-AFP producing 
cells. The transcriptional activation of humane HSP 
promoter found to be elevated to 59- to 662-times 6 h 
after heat treatment cells (43°C for 30min) compared 
to in PLC/PRF/5, HepG2 and HuH7 cells, respectively. 
 Our results of gene therapy studies demonstrated that 
AFP-tk or HSP-tk transduced hepatoma cells were sen-
sitive to GCV corresponding to transcriptional activa-
tion of human AFP-enhancer / promoter or humane 
HSP promoter, respectively. Thus, I-SP promoter or 
AFP-enhancer/ promoter seems to be .feasible for mo-
lecular targeting of HCC. 
 Serum glutamic-pyruvic transaminase (GPT) activ-
ity was measured as an indicator of liver dysfunction, 
since GPT is found primarily in the liver and released 
from damaged hepacytes. The recent study"' have 
demonstrated that serum transaminase levels were ele-
vated 8- to 16-fold above normal 7 days after the be-
ginning of Adenovirus-/9-gal (Ad9-gal) administration. 
Moreover, liver histopathology showed that severe 
hepatocellular necrosis with a markedly inflammatory
Fig. 4. (A): Blood test data from the mouse implanted with HuH7 cells. WBC count and BUN level were slightly 
elevated after the gene therapy, serum GPT activity increased up to 200 (I.U./l) 7 days after the CMV/GCV treatment. 
(B): Blood test data from eleven-month male nude mice (n=3). WBC counts, serum levels of BUN, and serum 
GPT activity were not found to be elevated after the gene therapy. Male nude mice were injected intraperitoneally 
with HVJ-anionic-liposome containing CMV-tk (40pg) (day 0). Ganciclovir was administered intraperitoneally 20 
mg/kg daily. To evaluate the side effects of the therapy, WBC count, BUN level and serum GPT activity were 
measured on day 0, day 4, day 7 and day 10. Each data point represents the mean±SEM.
Fig. 5 Nude mice implanted with HuH7 cells had bloody ascites and died 4 days after the beginning of CM 
V/GCV treatment Hematoxylin eosin stained liver (A) sections (x 100) Some inflammatory cells and many of 
HuH7 cells were observed (*) in liver section 
Hematoxylin eosin stained liver section of eleven month old nude mouse implanted with HCC cells (B) and of 
normal eleven month old nude mouse (C) (x400) The animals were sacrificed 10 days after the CMV/GCV 
treatment Hematoxylin eosin stained liver section in five week old nude mouse without HuH7 tumor (D) (x 
400) The animal implanted with HCC cells had some inflammatory cells (arrow in B) in liver, whereas control 
animals did not (C and D)
Table 1. Tumor growth in nude mice implanted with HuH7 
Mice used in these experiments were divided into three groups 
Group I, mock gene transfection (n=8), Group II, AFP tk 
transfection (n=11), and Group III, CMV tk transfection (n= 7 )
% Original Tumor Size
Time(Days) 0 9 18 
Control 100 488± 140 2793±743 
   "t 100 121+ 14 239+ 49 
   4k 100 140± 15 206± 39 
                                 *, * *, P<0.001
infiltrate in mice treated with Adl9-gal") On the other 
hand, after HVJ-liposome-mediated 19-gal administration, 
GPT activities were not elevated") In this study, after 
HVJ-liposome-mediated CMV TK/GCV gene therapy, GPT 
activities were not elevated and liver histopathology 
showed inflammation was small Thus, the toxicity of
HVJ anionic liposome mediated gene therapy is lower 
than that of adenovirus mediated one 
 Adenovirus-mediated gene therapy may be accompa 
need by the development of immunity, besides side 
effect In according with this, its effect becomes re 
stricted to regression of local tumor in clinical trials 
for cancer patients In contrast, HVJ-liposome is con-
structed from inactivated envelopes of the Sendai virus 
and liposome, therefore HVJ-liposome delivery system 
has low immunogenicity and is enabling repeated ad 
ministrations 1123) 
 Gene transfer using HVJ-liposome transfects not only 
tumor tissue but also various normal organ tissues 
However, significant induction of HSP-promoter or AFP-
enhancer/promoter activity in vivo was observed mostly 
in the tumor, and less efficiency in other organs AFP-tk 
gene therapy with HVJ liposome delivery system has
similar efficiency as CMV/HSV-tk in terms of tumor 
suppression. 
 Hence, hepatoma specific promoter, seems to be appli-
cable for gene therapy of HCC in humans. This strat-
egy, represents an improvement of conventional gene 
therapy, and contributes to an inducible and cell-specific 
gene therapy for advanced HCC.
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